Thomas D. Salus - 14 Apr 2026 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Reporting relationship: Chief Legal & Administration
Issuer ticker: LFCR
Reported as of: 14 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Apr 2026, 16:39:35 UTC
Prior SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron S. Perlitsh, Attorney-In-Fact for Thomas D Salus

Key filing fact

Thomas D. Salus filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 16 Apr 2026.

Key facts

This page summarizes Thomas D. Salus's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Apr 2026, 16:39.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002062209 Primary reporting owner

Salus Thomas D.

Relationship: Chief Legal & Administration
Address: C/O LIFECORE BIOMEDICAL, INC., 3515 LYMAN BLVD., CHASKA
Signature: /s/ Aaron S. Perlitsh, Attorney-In-Fact for Thomas D Salus
Signature date: 16 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LFCR transaction

Common Stock

Tax liability

Transaction value
Shares: -24,645
Change %: -9.1%
Price: $5.20^*
Shares after: 246,333
Date: 14 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.